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Retroelements comprise a large and successful family of transposable genetic elements
that, through intensive infiltration, have shaped the genomes of humans and other
mammals over millions of years. In fact, retrotransposons now account for approximately
45% of the human genome. Because of their genomic mobility called retrotransposition,
some retroelements can cause genetic diseases; such retrotransposition events occur not
only in germ cells but also in somatic cells, posing a threat to genomic stability throughout
all cellular populations. In response, mammals have developed intrinsic immunity
mechanisms that provide resistance against the deleterious effects of retrotransposition.
Among these, seven members of the APOBEC3 (A3) family of cytidine deaminases
serve as highly active, intrinsic, antiretroviral host factors. Certain A3 proteins effectively
counteract infections of retroviruses such as HIV-1, as well as those of other virus
families, while also blocking the transposition of retroelements. Based on their preferential
expression in the germ cells, in which retrotransposons may be active, it is likely that A3
proteins were acquired through mammalian evolution primarily to inhibit retrotransposition
and thereby maintain genomic stability in these cells. This review summarizes the recent
advances in our understanding of the interplay between the retroelements currently active
in the human genome and the anti-retroelement A3 proteins.
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INTRODUCTION
The evolution of vertebrate genomes has been driven in part
by the long history of their interaction with genetic transpos-
able elements. These so-called retrotransposons, which replicate
via RNA intermediates, can be divided into two groups depend-
ing on the presence or absence of long terminal repeats (LTRs).
LTR retrotransposons are endogenous retroviruses that constitute
nearly 10% of murine and human genomes, but they have been
rendered mostly inactive due to the accumulation of mutations,
although somemurine intracisternal A-particles (IAP) andMusD
sequences remain viable (Dewannieux et al., 2004; Ribet et al.,
2004). Non-LTR retrotransposons comprise themajority of trans-
posable elements; in fact, collectively, they account for more than
one third of the human genome. They can be further subdivided
into three types; long interspersed elements (LINEs), short inter-
spersed elements (SINEs), and the composite hominid-specific
retrotransposons, each of which contain the only transposable
elements currently active in the human genome, i.e., LINE-1, Alu,
and SINE-VNTR-Alu (SVA), respectively (Deininger and Batzer,
2002; Ostertag et al., 2003).
Retrotransposition, discussed in greater detail below, involves
the reverse transcription of an RNA intermediate with subsequent
genomic integration in a process driven by retrotransposon-
encoded RNA-dependent DNA polymerase and endonuclease.
The integration of these elements may have harmful conse-
quences for the host, compromising genomic stability via inser-
tions, deletions, and DNA rearrangements and thereby posing
a threat to human health, as described in several reports of
retrotransposition-induced genetic disorders (Kazazian et al.,
1988; Wallace et al., 1991; Kobayashi et al., 1998). In response,
eukaryotic organisms have evolvedmechanisms to restrict uncon-
trolled retrotransposition. Anti-retroelement strategies include
transcriptional silencing through DNA methylation (Walsh et al.,
1998; Bourc’his and Bestor, 2004; Burden et al., 2005), post-
transcriptional silencing via RNA interference (Soifer et al., 2005;
Yang and Kazazian, 2006), and some cellular factors inhibiting
retrotransposition at the post-translational level. Of these cellular
factors, seven members of the apolipoprotein B mRNA-editing
catalytic polypeptide-like 3 (APOBEC3; referred to hereafter as
the A3) family of cytidine deaminases have been shown to act as
potent inhibitors of a wide range of both exogenous retroviruses
and endogenous retroelements (Sheehy et al., 2002; Esnault et al.,
2005; Chen et al., 2006; Kinomoto et al., 2007). In this review,
we focus on active endogenous retroelements, their deleterious
effects on the human genome, and the anti-retroelement activity
of A3 proteins.
RETROTRANSPOSONS: AN OVERVIEW
Unlike the murine LTR retrotransposons IAP and MusD, human
versions, such as human endogenous retroviruses (HERV),
have been mostly fossilized, and even those that are not are
non-transposable. In contrast, many copies of human non-LTR
retrotransposons can replicate through an RNA/protein complex
intermediate and integrate into the host genome at a new site.
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The LINE retrotransposons, typified by LINE-1 (L1), account
for approximately 17% of the human genome, corresponding
to >500,000 copies (of which 100 copies are retrotransposition-
competent). L1 retrotransposons are 6 kb in length and con-
tain a 5′ untranslated region (UTR) that harbors a Pol II
promoter; two ORFs necessary for their own replication; and
a 3′ UTR containing a polyadenylation signal, followed by a
poly(A) tail (Figure 1A, top). Briefly, L1 elements are first tran-
scribed by RNA-polymerase II using a promoter located at the
L1 5′ region (Ostertag and Kazazian, 2001). ORF1, encoding
an RNA-binding protein, and ORF2, encoding a protein with
reverse transcriptase and endonuclease activity, are then trans-
lated in the cytoplasm. The resulting proteins associate with
L1 RNA to form a ribonucleoprotein (RNP) complex (Martin,
1991; Hohjoh and Singer, 1996; Figure 1B) that is transported
back into the nucleus, where L1 is integrated into the host
genome through a target-primed reverse transcription (Cost
et al., 2002).
The human genome also contains more than 1 million copies
of Alu elements; these are the most common SINE retrotrans-
posons, representing 11% of our genome. The typical Alu ele-
ment is approximately 300 bp in length and is formed by the
fusion of two 7SL-RNA gene-derived monomers separated by
an A-rich linker, followed by a poly(A) tail (Kriegs et al., 2007;
Figure 1A, middle). Likewise, there are ∼2700 copies of the
composite SVA elements in the human genome. SVAs, which
are approximately 2 kb long, are composed of CCCTCT hexam-
eric repeats that are followed by an inverted Alu-like region, a
region containing a variable number of tandem repeats (VNTRs),
and a partial HERV-K env–LTR sequence termed SINE-R that
ends with a polyadenylation signal, followed by a poly(A) tail
(Ostertag et al., 2003; Figure 1A, bottom). Unlike L1, Alu and
SVA elements are non-autonomous since they do not encode
functional reverse transcriptase or endonuclease; instead, they
use the enzymatic machinery of L1 for retrotransposition. Once
Alu and SVA elements have been transcribed and exported
to the cytoplasm, they hijack the L1-encoded enzymes in the
vicinity of the ribosomes through mechanisms that are as-yet
unclear (Figure 1C; Dewannieux et al., 2003; Ostertag et al.,
2003).
RETROTRANSPOSONS IN HUMAN DISEASES
Approximately 100 examples of disease-causing retrotransposon
insertions are currently reported in the literature. It is esti-
mated that de novo insertions of L1, Alu, and SVA elements
are responsible for approximately 0.3% of all disease-causing
human mutations, corresponding to event rates of 1:100, 1:20,
and 1:900 births, respectively (Cordaux and Batzer, 2009). L1-
induced genetic diseases include the following: Duchenne mus-
cular dystrophy and X-linked dilated cardiomyopathy, resulting
from insertions in the dystrophin gene (Narita et al., 1993;
Yoshida et al., 1998); progressive chorioretinal degeneration,
caused by the CHM gene disruption (van den Hurk et al.,
2003); hemophilia A and B, due to insertions in the factor
VIII and IX genes, respectively (Kazazian et al., 1988; Li et al.,
2001; Mukherjee et al., 2004); and chronic granulomatous disease,
the result of a mutation arising from an insertion in the CYBB
gene (Meischl et al., 2000). Genetic diseases linked to Alu inte-
gration events include neurofibromatosis via an insertion in the
NF1 gene (Wallace et al., 1991; Wimmer et al., 2011); Apert
syndrome, a severe autosomal dominant disorder, due to inte-
gration of the element into the fibroblast growth-factor receptor
2 (FGFR2) gene (Oldridge et al., 1999); and progressive renal
failure (Dent’s disease) due to disruption of the renal chlo-
ride channel (CLCN5) gene (Claverie-Martin et al., 2005). The
involvement of SVA retrotransposition in human diseases has
also been documented; namely, an insertion in the ARH gene
leads to autosomal recessive hypercholesterolemia (Wilund et al.,
2002); disruption of the BTK gene causes X-linked agamma-
globulinemia (XLA; Rohrer et al., 1999); and disruption of the
fukutin gene results in Fukuyama-type congenital muscular dys-
trophy (Kobayashi et al., 1998). Importantly, ongoing retrotrans-
poson insertions seem to occur not only in germ cells and early
embryos but also in brain tissues (Coufal et al., 2009; Baillie
et al., 2011), somatic cells in vitro (Kubo et al., 2006; Rangwala
et al., 2009), and somatic malignant tissues (Economou-Pachnis
and Tsichlis, 1985; Morse et al., 1988; Miki et al., 1992). Several
reports have also shown retrotransposon-induced recombination
in certain types of cancer (Schichman et al., 1994; Jeffs et al.,
1998).
CELLULAR MECHANISMS LIMITING THE ACTIVITY OF
RETROELEMENTS AND RETROVIRUSES
As noted above, since unrestricted retrotransposition would
result in genome instability, eukaryotic organisms have devel-
oped several strategies to restrict these mobile elements. Firstly,
retrotransposition can be regulated at the transcriptional level
through several transcription factors. For example, L1 transcrip-
tion is positively regulated by SOX11 (Tchenio et al., 2000),
RUNX3 (Yang et al., 2003) and YY1 (Athanikar et al., 2004),
and negatively regulated by SRY (Tchenio et al., 2000) and SOX2
(Muotri et al., 2005). DNA methylation by the methyl-CpG-
binding protein MeCP2 results in the repression of L1 tran-
scription in neurons (Walsh et al., 1998; Burden et al., 2005;
Muotri et al., 2010). Secondly, retrotransposable elements are
also susceptible to post-transcriptional regulation. For instance,
endogenously encoded small interfering RNAs have been shown
to reduce L1 retrotransposition in vitro (Soifer et al., 2005; Yang
and Kazazian, 2006). Additionally, L1 transcripts that contain
multiple polyadenylation signals lead to premature polyadeny-
lation, resulting in the attenuation of L1 activity via truncation
of its full-length transcripts (Perepelitsa-Belancio and Deininger,
2003). Thirdly, some cellular factors regulate retrotransposi-
tion at the post-translational level. In mice, the 3′–5′ exonu-
clease Trex1 digests retroelement-derived DNA to suppress the
autoimmune response (Stetson et al., 2008), Consistent with
this, mutations in human Trex1 cause autoimmune diseases like
familial chilblain lupus and Aicardi-Goutieres syndrome (Crow
et al., 2006). Likewise, HIV-1 restriction factors such as the
cytidine deaminases, the focus of this review, can inhibit L1
and Alu retrotransposition through a mechanism that is still
unknown.
In humans, the cellular cytidine deaminase family com-
prises several members, including activation-induced cytidine
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FIGURE 1 | Retrotranspositioncycle.Schematic representationof active
humanretrotransposons. (A)Top:L1genomicorganization, fromthe left:5′UTR,
untranslated region;ORF-1, encodinganRNA-bindingprotein; linker region;
ORF-2, encoding reverse transcriptase andendonuclease;3′UTR;AAA, poly(A)
tail.Middle: Alu organization, from the left: 7SL-derivedmonomer;A-rich linker,
A5TACA6; 7SL-derivedmonomer;AAA, poly(A) tail.Bottom: SVAorganization,
from the left: (CCCTCT)n, hexamer repeat; invertedAlu-likesequence;VNTR,
variable numberof tandemrepeats;SINE-R,HERV-K-derivedsequence;
AAA, poly(A) tail. (B)Retrotransposition cycle: L1elements are transcribedby
RNA-polymerase II fromanL1promoter sequence. TheL1mRNAtemplate is
exported to the cytoplasmand translated.Retrotransposon-encodedproteins
activelybind theL1RNAtranscript, forminga ribonucleoproteinparticle (RNP)
that is importedback into thenucleus.There, theL1-encodedendonucleasenicks
anL1 target sequence (5′-TTTT/AA-3′) and the3′-OHgenerated isused asa
primer for target-primed reverse transcription (TPRT) by theL1-encoded reverse
transcriptase, resulting indenovo integration into thehost genome. (C)Aluas
well asSVAelementsare transcribed andhijack theL1-encodedenzymatic
machinery to complete their respective retrotranspositioncycles.
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deaminase (AID), APOBEC1, APOBEC2, the A3 family, and
APOBEC4 (Harris and Liddament, 2004; Conticello, 2008; Smith
et al., 2012). APOBEC1 is the catalytic subunit of an RNA-editing
complex that deaminates C6666 →U in the mRNA of the lipid-
transport protein apolipoprotein B, thereby creating a premature
stop codon that leads to a truncated protein in gastrointesti-
nal tissues (Teng et al., 1993). APOBEC1 proteins from multiple
small-animal species exhibit inhibitory activity against not only
exogenous retroviruses (Ikeda et al., 2008) but also endogenous
retroviruses, such as murine IAP and MusD sequences, as well
as L1 elements (Ikeda et al., 2011). AID plays a role in the
adaptive humoral immune system by inducing somatic hyper-
mutations and class switch recombination, which allows affinity
maturation andmemory development; however, its precisemech-
anism of action remains to be determined (Honjo et al., 2005).
As described in detail in a subsequent section, members of the
A3 family are potent inhibitors of both exogenous retroviruses
and endogenous retroelements. A3G, the most extensively stud-
ied member of the A3 family, was the first cytidine deaminase
shown to restrict infection by Vif-deficient HIV-1 viruses. Briefly,
as depicted in Figure 2, A3G is incorporated into budding viri-
ons and thus exerts its antiviral effect at the post-entry step in
target cells, either by mediating extensive deamination of the
minus-strand of viral DNA during reverse transcription, which
results in G→A hypermutations in the proviral DNAplus strand
(deaminase-dependent mechanism) (Harris et al., 2003; Mangeat
et al., 2003; Zhang et al., 2003), or by binding to HIV-1 RNA, lead-
ing to physical impairment of reverse transcription (deaminase-
independent mechanism; Newman et al., 2005; Bishop et al.,
2006; Iwatani et al., 2007). Consequently, primate lentiviruses
have evolved to counteract the antiretroviral activity of A3G by
acquiring Vif. This accessory protein prevents A3G incorporation
into virions through its proteasomal degradation (Marin et al.,
2003; Sheehy et al., 2003; Stopak et al., 2003). We and others have
shown that Vif proteins derived from different HIV-1 subtypes
differ in their potency of A3G inhibition, suggesting differen-
tial levels of viral fitness among clades (Iwabu et al., 2010; Binka
et al., 2012). APOBEC2, a cardiac- and skeletal muscle-specific
cytidine deaminase, is required for muscle development and
early embryogenesis (Etard et al., 2010; Sato et al., 2010; Vonica
et al., 2011). The physiological role of APOBEC4 remains to be
determined.
DIFFERENTIAL ANTIVIRAL AND ANTI-RETROELEMENT
ACTIVITIES OF A3 CYTIDINE DEAMINASES
Members of the A3 family contain either single (A3A, A3C,
A3H) or double (A3B, A3DE, A3F, and A3G) cytidine deam-
inase domains (CDA). In A3G and A3F, the N-terminal CDA
is responsible for RNA-dependent oligomerization, while the
C-terminal CDA mainly mediates the deamination of single-
stranded DNA (Hache et al., 2005; Newman et al., 2005). Some
A3 family members strongly inhibit a wide range of exogenous
retroviruses, as well as other viral pathogens, including her-
pesviruses, parvoviruses, papillomaviruses, and hepadnaviruses
(Baumert et al., 2007; Vartanian et al., 2008; Narvaiza et al., 2009;
Suspène et al., 2011b). The importance of A3 proteins in vivo
has been demonstrated in murine studies in which mice lack-
ing the A3 gene were shown to be more susceptible to viral
infection than their wild-type counterparts (Okeoma et al., 2007,
2009; Takeda et al., 2008). A3 proteins also inhibit the mobi-
lization of endogenous retroviruses, such as MusD, IAP, and the
yeast LTR-retrotransposon Ty1 (Esnault et al., 2005; Schumacher
et al., 2008), in addition to their inhibitory activity on L1 and
Alu retrotransposition. The gene copy number of A3 family
members is species-specific in mammals, in which except for pri-
mates, one, two, or three A3 proteins are encoded, whereas in
humans and in non-human primates, seven A3 proteins have
been recognized (A3A, A3B, A3C, A3DE, A3F, A3G, and A3H;
Sawyer et al., 2004; OhAinle et al., 2006). Of note, expansion
of the A3 gene cluster in primate genomes correlates with a
FIGURE 2 | Mechanisms of antiretroviral and anti-retroelement activity
of A3G protein. A3G potently restricts Vif-deficient HIV-1 viruses: A3G is
incorporated into virus particles in virus-producing cells. Following the
infection of target cells, A3G inhibits viral replication either by binding to
HIV-1 RNA, leading to physical blocking of reverse transcription
(deaminase-independentmechanism), or by deaminating the viral
minus-strand DNA during reverse transcription, thus generating G → A
hypermutations in the proviral DNA plus strand.
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sharp reduction in retrotransposition activity, suggesting that
these restriction factors have evolved to protect mammalian
hosts from retroelements (Sawyer et al., 2004; Schumann, 2007).
Antiretroviral and anti-retroelement potencies were shown to dif-
fer in the seven members of A3 family, independently of their
subcellular localization (Kinomoto et al., 2007). However, the
exact mechanism by which A3 proteins inhibit retrotranspo-
sition is unclear. The current findings on antiviral and anti-
retroelement activities of A3members are summarized below and
in Table 1.
A3A
Human A3A (hA3A) lacks inhibitory activity against HIV-1 pro-
duced from 293T cells overexpressing this protein (Bishop et al.,
2004; Bogerd et al., 2006a; Kinomoto et al., 2007; Hultquist et al.,
2011), since it is not incorporated into virions (Goila-Gaur et al.,
2007; Aguiar et al., 2008). In human monocytic cells as targets,
however, hA3A blocks the early phase of HIV-1 infection (Peng
et al., 2007; Koning et al., 2011) but is counteracted by the HIV-
2/SIV (simian immunodeficiency virus) accessory protein Vpx
(Berger et al., 2010, 2011). Also, hA3A can inhibit infections by
adeno-associated virus (Chen et al., 2006; Narvaiza et al., 2009),
human papillomavirus (HPV; Vartanian et al., 2008), porcine
endogenous retrovirus (PERV; Dörrschuck et al., 2011), and
human T-cell leukemia virus type 1 (HTLV-1; Ooms et al., 2012).
Importantly, in vitro overexpression experiments have demon-
strated that hA3A effectively inhibits the retrotranspositions of
L1, Alu (Bogerd et al., 2006b; Chen et al., 2006; Muckenfuss
et al., 2006; Kinomoto et al., 2007; Niewiadomska et al., 2007;
Tan et al., 2009; Khatua et al., 2010; Ikeda et al., 2011), IAP, and
MusD (Bogerd et al., 2006a; Chen et al., 2006; Ikeda et al., 2011)
through a deaminase-independent mechanism. hA3A is intrin-
sically able to restrict infection of the genetically reconstituted
HERV-K in a deaminase-dependent manner (Lee et al., 2008). In
a recent report, hA3A was shown to induce somatic hypermu-
tation in human mitochondrial and nuclear DNA; in the latter,
this included genes associated with the development of cancer
(Suspène et al., 2011a).
A3B
Human A3B (hA3B) is the sole member of the A3 family with an
exclusive nuclear localization (Bogerd et al., 2006a; Muckenfuss
et al., 2006; Stenglein and Harris, 2006; Kinomoto et al., 2007;
Pak et al., 2011), sharing a common nuclear import mecha-
nism with AID (Lackey et al., 2012). hA3B inhibits infections
of HIV-1 and SIV, independently of the presence of Vif (Bishop
et al., 2004; Yu et al., 2004; Doehle et al., 2005a; Hultquist
et al., 2011). Since hA3B expression is extremely low in target
CD4+ T-cells (Bishop et al., 2004; Doehle et al., 2005a; Koning
et al., 2009; Refsland et al., 2010), Vif might have failed to
evolve the mechanism to antagonize this antiretroviral factor.
Also, hA3B restricts infections by murine leukemia virus (MLV;
Doehle et al., 2005b; Kinomoto et al., 2007), PERV (Dörrschuck
et al., 2011), HTLV-1 (Ooms et al., 2012), and Rous sarcoma
virus (RSV; Wiegand and Cullen, 2007). Like hA3A, in vitro
overexpression of hA3B inhibits the retrotranspositions of L1,
Alu (Bogerd et al., 2006b; Muckenfuss et al., 2006; Stenglein
and Harris, 2006; Kinomoto et al., 2007; Niewiadomska et al.,
2007; Khatua et al., 2010; Ikeda et al., 2011), IAP, and MusD
(Bogerd et al., 2006a; Chen et al., 2006; Ikeda et al., 2011) in
a deaminase-independent manner, while inhibiting the reconsti-
tuted HERV-K infection through a deaminase-dependent mecha-
nism (Lee et al., 2008). In a recent study, endogenously expressed
hA3B effectively restricted L1 retrotransposition in both trans-
formed cells and human embryonic stem cells (Wissing et al.,
2011).
A3C
Human A3C (hA3C) is abundantly expressed in numerous tissues
and cell types (Jarmuz et al., 2002), and its expression is unre-
sponsive to interferon-α (Koning et al., 2009). Although hA3C
is efficiently incorporated into retroviral particles, it exhibits
only partial antiviral activity against HIV-1, with or without
Vif (Bishop et al., 2004; Yu et al., 2004; Bogerd et al., 2006a;
Hultquist et al., 2011). By contrast, hA3C is able to efficiently
block the replication of SIV, which also encapsidates this pro-
tein but is readily antagonized by SIV Vif (Yu et al., 2004). hA3C
can inhibit infection of primate foamy virus (PFV), which car-
ries an hA3 antagonistic Bet protein (Russell et al., 2005; Perkovic´
et al., 2009). The overexpression of hA3C results in a moder-
ate inhibition of L1 and Alu retrotranspositions (Bogerd et al.,
2006b; Chen et al., 2006; Muckenfuss et al., 2006; Kinomoto et al.,
2007; Niewiadomska et al., 2007; Khatua et al., 2010) but effec-
tively inhibits those of IAP, MusD, and Ty1 (Dutko et al., 2005;
Chen et al., 2006). In a recent study, hA3C was shown to restrict
infections by MLV (Langlois et al., 2005; Kinomoto et al., 2007),
hepatitis B virus (HBV; Baumert et al., 2007; Köck and Blum,
2008), HPV (Vartanian et al., 2008), herpes simplex virus 1 and
Epstein-Barr virus (Suspène et al., 2011b).
A3DE
Human A3DE (hA3DE) overexpression has moderate effects
on L1 and Alu retrotransposition (Stenglein and Harris, 2006;
Kinomoto et al., 2007; Niewiadomska et al., 2007; Tan et al., 2009;
Duggal et al., 2011). Similarly, hA3DE exhibits low levels of anti-
HIV-1 and anti-SIV activities, both of which are antagonized by
the respective Vif proteins (Dang et al., 2006; Hultquist et al.,
2011). The reduced activity is determined by a cysteine residue
located at amino acid position 320 of hA3DE. Substitution with
the corresponding tyrosine present in A3F resulted in a 20-
fold increase of A3DE activity (Dang et al., 2011). Indeed, the
chimpanzee version of A3DE, carrying a tyrosine residue at this
position, shows much higher antiretroviral activity, while both
human and chimpanzee A3DEs exhibit similar levels of inhibition
against retroelements, suggesting that the host defense activity
of A3DE against retroelements has been evolutionarily conserved
(Duggal et al., 2011).
A3F/A3G
With regard to the antiretroviral potencies of humanA3G (hA3G)
and A3F (hA3F) proteins, overwhelming amount of informa-
tion is well-summarized elsewhere (Harris and Liddament, 2004;
Huthoff and Towers, 2008; Malim, 2009). Similar to hA3G, as
introduced in the previous section, hA3F has been shown to
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Table 1 | Antiviral and anti-retroelement spectrum of A3 family members.






AAV (Chen et al.,
2006; Narvaiza
et al., 2009)
HIV-1 (Peng et al., 2007; Koning et al.,
2011; Schmitt et al., 2011)
IAP (Chen et al., 2006;
Ikeda et al., 2011)
MusD (Bogerd et al.,
2006a; Chen et al., 2006)
L1 (Bogerd et al., 2006b; Chen et al., 2006;
Muckenfuss et al., 2006; Kinomoto et al.,
2007; Niewiadomska et al., 2007; Tan




SIV (Schmitt et al., 2011) PERV (Dörrschuck et al.,
2011)
Alu (Bogerd et al., 2006b; Muckenfuss
et al., 2006; Niewiadomska et al., 2007;
Tan et al., 2009; Khatua et al., 2010)
HTLV-1 (Ooms et al., 2012) Reconstituted HERV-K (Lee et al., 2008)
A3B
(N)
HIV-1 (Bishop et al., 2004; Doehle et al.,
2005a; Bogerd et al., 2006a; Kinomoto
et al., 2007; Hultquist et al., 2011)
SIV (Yu et al., 2004)
IAP (Bogerd et al.,
2006a; Chen et al., 2006;
Ikeda et al., 2011)
MusD (Chen et al., 2006;
Ikeda et al., 2011)
L1 (Bogerd et al., 2006b; Muckenfuss
et al., 2006; Stenglein and Harris, 2006;
Kinomoto et al., 2007; Niewiadomska
et al., 2007; Khatua et al., 2010; Ikeda
et al., 2011; Wissing et al., 2011)
HTLV-1 (Ooms et al., 2012) PERV (Dörrschuck et al.,
2011)
Alu (Bogerd et al., 2006b; Muckenfuss
et al., 2006; Stenglein and Harris, 2006;
Niewiadomska et al., 2007)
MLV (Doehle et al., 2005b; Kinomoto
et al., 2007)
Reconstituted HERV-K (Lee et al., 2008)








HIV-1 (Bishop et al., 2004; Yu et al.,
2004; Bogerd et al., 2006a; Hultquist
et al., 2011)
IAP (Chen et al., 2006)
MusD (Chen et al., 2006)
L1 (Bogerd et al., 2006b; Chen et al., 2006;
Muckenfuss et al., 2006; Kinomoto et al.,




SIV (Yu et al., 2004)
PFV (Russell et al., 2005; Perkovic´
et al., 2009)
Ty1 (Dutko et al., 2005) Alu (Bogerd et al., 2006b; Muckenfuss
et al., 2006; Niewiadomska et al., 2007;
Khatua et al., 2010)
EBV (Suspène
et al., 2011b)




HIV-1 (Dang et al., 2006; Hultquist
et al., 2011)
L1 (Stenglein and Harris, 2006; Kinomoto
et al., 2007; Niewiadomska et al., 2007;
Duggal et al., 2011)
SIV (Dang et al., 2006) Alu (Tan et al., 2009)
A3F
(C)
HIV-1 (Wiegand et al., 2004; Zheng
et al., 2004; Bishop et al., 2006;
Holmes et al., 2007; Yang et al., 2007)
IAP (Chen et al., 2006)
MusD (Chen et al., 2006)
L1 (Turelli et al., 2004a; Muckenfuss et al.,
2006; Stenglein and Harris, 2006;
Kinomoto et al., 2007; Niewiadomska
et al., 2007; Khatua et al., 2010)
SIV (Bogerd et al., 2004; Mangeat
et al., 2004; Schröfelbauer et al., 2004)
Ty1 (Dutko et al., 2005;
Schumacher et al., 2005)
Reconstituted HERV-K (Lee and Bieniasz,
2007; Lee et al., 2008)
XMRV (Paprotka et al., 2010) PERV (Dörrschuck et al.,
2011)
PFV (Russell et al., 2005; Delebecque
et al., 2006)
MLV (Langlois et al., 2005)
RSV (Wiegand and Cullen, 2007)
MPMV (Doehle et al., 2006)
(Continued)
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Table 1 | Continued






HBV (Turelli et al.,
2004a; Köck and
Blum, 2008)
HIV-1 (Harris et al., 2003; Mangeat
et al., 2003; Zhang et al., 2003;
Newman et al., 2005; Bishop et al.,
2006)
IAP (Esnault et al., 2005;
Ikeda et al., 2011)
L1 (Kinomoto et al., 2007; Niewiadomska
et al., 2007; Khatua et al., 2010; Ikeda
et al., 2011)
SIV (Bogerd et al., 2004; Mangeat
et al., 2004; Schröfelbauer et al., 2004)
MusD (Esnault et al.,
2005; Chen et al., 2006;
Schumacher et al., 2008;
Ikeda et al., 2011)
Alu (Chiu et al., 2006; Hulme et al., 2007;
Bulliard et al., 2009; Tan et al., 2009)
MLV (Harris et al., 2003; Kobayashi
et al., 2004; Doehle et al., 2005b;
Langlois et al., 2005; Kinomoto et al.,
2007)
Ty1 (Dutko et al., 2005;
Schumacher et al., 2005)
Reconstituted HERV-K (Lee et al., 2008)
XMRV (Groom et al., 2010; Paprotka
et al., 2010)
PERV (Jónsson et al.,
2007; Dörrschuck et al.,
2011)
PFV (Russell et al., 2005; Delebecque
et al., 2006)
MMTV (Okeoma et al., 2007)
EIAV (Bogerd et al., 2008)
HTLV-1 (Sasada et al., 2005; Fan et al.,
2010)
RSV (Wiegand and Cullen, 2007)





HIV-1 (OhAinle et al., 2008; Harari
et al., 2009; Li et al., 2010; Zhen et al.,
2010; Wang et al., 2011)
PERV (Dörrschuck et al.,
2011)
L1 (Kinomoto et al., 2007; OhAinle et al.,
2008; Tan et al., 2009)
HBV (Köck and
Blum, 2008)
HTLV-1 (Ooms et al., 2012) Alu (Tan et al., 2009)
(C), cytoplasmic localization; (N), nuclear localization; (C/N), diffuse cytoplasmic/nuclear localization; AAV, Adeno-associated virus; HPV, Human papillomavirus; HBV,
Hepatitis B virus; HSV-1, Herpes simplex virus 1; EBV, Epstein-Barr virus; MLV, Murine leukemia virus; RSV, Rous sarcoma virus; PFV, Primate foamy virus; XMRV,
Xenotropic murine leukemia virus-related virus; MPMV, Mason-Pfizer Monkey Virus; MMTV, Mouse mammary tumor virus; HTLV-1, Human T-cell leukemia virus
type 1; EIAV, Equine infectious anemia virus; IAP, Intracisternal A particles; PERV, Porcine endogenous retrovirus; L1, Long interspersed element 1; HERV-K, Human
endogenous retrovirus K.
potently restrict the replication of Vif-deficient HIV-1 viruses
in target cells after its incorporation into budding virions
through both deaminase-dependent and -independent mecha-
nisms (Bishop et al., 2004; Wiegand et al., 2004; Zheng et al.,
2004; Holmes et al., 2007; Yang et al., 2007). The in vitro over-
expression of hA3G inhibits not only retroviral infections, such
as those by HTLV-1 (Sasada et al., 2005; Fan et al., 2010),
SIV (Bogerd et al., 2004; Mangeat et al., 2004; Schröfelbauer
et al., 2004), PFV (Russell et al., 2005; Delebecque et al., 2006),
equine infectious anemia virus (Bogerd et al., 2008), MLV (Harris
et al., 2003; Kobayashi et al., 2004; Doehle et al., 2005b; Langlois
et al., 2005; Kinomoto et al., 2007), Mason-Pfizer monkey virus
(MPMV; Doehle et al., 2006), xenotropic murine leukemia virus-
related virus (XMRV; Groom et al., 2010; Paprotka et al., 2010),
PERV (Jónsson et al., 2007; Dörrschuck et al., 2011), and RSV
(Wiegand and Cullen, 2007), but also retrotranspositions of
non-human LTR retroelements, such as IAP, MusD, and Ty1
(Dutko et al., 2005; Esnault et al., 2005; Chen et al., 2006;
Schumacher et al., 2008; Ikeda et al., 2011). This cytidine deam-
inase is also effective against HBV (Turelli et al., 2004a; Köck
and Blum, 2008). With regard to potential to inhibit L1 retro-
transposition, conflicting results have been reported; some lines
of evidence suggest that hA3G has anti-Alu activity (Chiu et al.,
2006; Hulme et al., 2007; Bulliard et al., 2009; Tan et al., 2009)
but little or no anti-L1 activity (Turelli et al., 2004b; Bogerd
et al., 2006b; Muckenfuss et al., 2006; Stenglein and Harris,
2006). We and others, however, have shown that hA3G is also
able to restrict L1 retrotransposition, albeit less potently than
hA3A or hA3B, through deaminase-independent mechanisms
(Kinomoto et al., 2007; Niewiadomska et al., 2007; Khatua
et al., 2010; Ikeda et al., 2011). These discrepancies might be
due to cell-type differences in hA3 protein expression levels, as
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we have described previously (Kinomoto et al., 2007). A puta-
tive mechanism of L1 inhibition by hA3G is as follows: When
L1 forms the RNP complex in the cytoplasm (Figure 1B, right
half), cytoplasmic hA3G protein might be able to access the com-
plex through the interaction with L1 RNA, and then enter the
nucleus together with the complex. This could result in the effec-
tive inhibition of L1 reverse transcription, by physically blocking
the access to the chromosomal DNA, or by impeding the move-
ment of the reverse transcriptase on a template L1 RNA. In the
case of the infection by reconstituted HERV-K, hA3G carries
out deamination showing only marginal inhibition of infectivity
(Lee et al., 2008). Among the viruses and retroelements described
above, hA3F is known to inhibit infections of PFV (Russell et al.,
2005; Delebecque et al., 2006), MLV (Langlois et al., 2005), XMRV
(Paprotka et al., 2010), MPMV (Doehle et al., 2006), PERV
(Dörrschuck et al., 2011), RSV (Wiegand and Cullen, 2007), and
reconstituted HERV-K (Lee and Bieniasz, 2007; Lee et al., 2008),
as well as the retrotransposons; L1 (Chen et al., 2006; Muckenfuss
et al., 2006; Stenglein and Harris, 2006; Kinomoto et al., 2007;
Niewiadomska et al., 2007; Khatua et al., 2010), Ty1 (Dutko et al.,
2005; Schumacher et al., 2005), MusD and IAP (Chen et al., 2006).
A3H
Human A3H (hA3H) is the most distantly related of the
hA3 members and is known for its functional polymorphisms.
Currently, four major haplotypes (I–IV) have been identified in
human populations, among which haplotype I has the highest
allelic frequencies (OhAinle et al., 2008). Haplotypes I, III, and IV
generate unstable proteins with very little, if any, antiretroviral
and anti-retroelement activity. Haplotype II, however, expresses
a stable protein with relatively high inhibitory activity on HIV-1
(OhAinle et al., 2008; Harari et al., 2009; Li et al., 2010; Zhen
et al., 2010; Wang et al., 2011) and HTLV-1 (Ooms et al., 2012),
and its overexpression effectively restricts L1 retrotransposition
(OhAinle et al., 2008; Tan et al., 2009). These observations sug-
gest that the relative lack of anti-retroviral and anti-retroelement
potencies in hA3H is not due to insufficient enzymatic activ-
ity but to the instability of the protein. It should be noted that
hA3H haplotype II is mainly localized to the cytoplasm, while
the haplotype I protein passively diffuses into the nucleus (Li and
Emerman, 2011). The ability of hA3H to block infections of HPV
(Vartanian et al., 2008), HBV (Köck and Blum, 2008), and PERV
(Dörrschuck et al., 2011) has also been reported, although the
responsible haplotypes have not been described.
CONCLUDING REMARKS
Retrotransposable elements have successfully proliferated over
tens of millions of years of mammalian evolution, such that they
now constitute 45% of the human genome. Retrotransposition
spreads DNA fragments to different genomic sites and is thus
considered to be one of the driving forces in genome evolu-
tion by contributing to the formation of new genes. On the
other hand, the price to pay for such genomic innovation, in
which retrotransposons integrate in their host genomes, is the
potential disruption of essential genes, resulting in deleterious
effects, some of which are clearly associated with genetic dis-
eases and tumorigenesis. Consequently, to prevent uncontrolled
retrotransposition, host organisms have evolved several defense
mechanisms. Among these, the seven members of A3 family have
the ability to restrict not only a broad range of exogenous retro-
viruses but also endogenous retroelements, as described herein.
Interestingly, high-level A3 expression is seen in the testis and
ovary and in embryonic stem cells (Jarmuz et al., 2002; Bogerd
et al., 2006b; OhAinle et al., 2006), in which the retroelements
are hypomethylated and therefore active (Bourc’his and Bestor,
2004; Dupressoir and Heidmann, 1996). These findings support
the evolutionary acquisition of A3 proteins to protect these cells
primarily from the genomic instability caused by the disruptive
effect of endogenous retroelements. Further investigations of A3-
mediated intrinsic immunity are likely to provide insights into
the molecular mechanisms of the host defenses that do not allow
retrotransposons to escape from the seven members of A3.
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